[go: up one dir, main page]

AU2005266739A1 - Carrier for medicaments for obtaining oral bioavailability - Google Patents

Carrier for medicaments for obtaining oral bioavailability Download PDF

Info

Publication number
AU2005266739A1
AU2005266739A1 AU2005266739A AU2005266739A AU2005266739A1 AU 2005266739 A1 AU2005266739 A1 AU 2005266739A1 AU 2005266739 A AU2005266739 A AU 2005266739A AU 2005266739 A AU2005266739 A AU 2005266739A AU 2005266739 A1 AU2005266739 A1 AU 2005266739A1
Authority
AU
Australia
Prior art keywords
protein
complex
protein complex
insulin
anyone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005266739A
Other languages
English (en)
Inventor
Jurgen Frevert
Thomas Stibora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotecon Therapeutics GmbH
Original Assignee
Biotecon Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Therapeutics GmbH filed Critical Biotecon Therapeutics GmbH
Publication of AU2005266739A1 publication Critical patent/AU2005266739A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2005266739A 2004-07-22 2005-07-22 Carrier for medicaments for obtaining oral bioavailability Abandoned AU2005266739A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004035606A DE102004035606A1 (de) 2004-07-22 2004-07-22 Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit
DE102004035606.8 2004-07-22
PCT/DE2005/001290 WO2006010360A2 (fr) 2004-07-22 2005-07-22 Vehicule permettant d'obtenir des medicaments a biodisponibilite orale

Publications (1)

Publication Number Publication Date
AU2005266739A1 true AU2005266739A1 (en) 2006-02-02

Family

ID=35482323

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005266739A Abandoned AU2005266739A1 (en) 2004-07-22 2005-07-22 Carrier for medicaments for obtaining oral bioavailability

Country Status (13)

Country Link
EP (1) EP1768701A2 (fr)
JP (1) JP2008506724A (fr)
KR (1) KR20070047786A (fr)
CN (1) CN101340932A (fr)
AU (1) AU2005266739A1 (fr)
BR (1) BRPI0513715A (fr)
CA (1) CA2574124A1 (fr)
DE (1) DE102004035606A1 (fr)
IL (1) IL180229A0 (fr)
MX (1) MX2007000421A (fr)
NO (1) NO20070775L (fr)
RU (1) RU2006147284A (fr)
WO (1) WO2006010360A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008169166A (ja) * 2007-01-14 2008-07-24 Tokyo Univ Of Agriculture & Technology 糖結合性ポリペプチド、複合材料、及び薬剤送達システム
JP2009132686A (ja) * 2007-10-26 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチド及びボツリヌス毒素の検出方法
WO2009131435A1 (fr) * 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Lieur contenant de la bungarotoxine et un peptide de liaison
EP2512519A2 (fr) * 2009-12-18 2012-10-24 Allergan, Inc. Complexe originant du clostridium botulinum comme vecteur pour l'administration d' agents therapeutiques
WO2013010782A2 (fr) 2011-07-15 2013-01-24 Nxp.B.V. Commande d'un convertisseur résonant
CN108137654A (zh) * 2015-05-15 2018-06-08 内布拉斯加大学董事会 适用于将分子递送进入选定细胞的工程改造的肉毒梭菌毒素
CN115894719B (zh) * 2022-11-24 2023-10-20 武汉禾元生物科技股份有限公司 一种人血清白蛋白胰岛素偶联物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8914984D0 (en) * 1989-06-29 1989-08-23 Animal Health Inst Nucleotide sequences
EP0866718A1 (fr) * 1995-12-13 1998-09-30 President And Fellows Of Harvard College Utilisation de peptides de toxine et/ou de marqueurs d'affinite pour l'introduction de composes dans des cellules
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9824282D0 (en) * 1998-11-05 1998-12-30 Microbiological Research Agenc Delivery of superoxide dismutase to neuronal cells
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
US6776990B2 (en) * 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
WO2003061694A1 (fr) * 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression de la reponse immune humorale par des anticorps anti-cd20
GB0112687D0 (en) * 2001-05-24 2001-07-18 Microbiological Res Authority Pharmaceutical use of secreted bacterial effector proteins
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
JP2007070225A (ja) * 2003-07-25 2007-03-22 Yukako Fujinaga クロストリジウム属菌由来成分を含む医薬製剤
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins

Also Published As

Publication number Publication date
KR20070047786A (ko) 2007-05-07
NO20070775L (no) 2007-04-18
EP1768701A2 (fr) 2007-04-04
WO2006010360A3 (fr) 2007-12-27
WO2006010360A2 (fr) 2006-02-02
JP2008506724A (ja) 2008-03-06
CN101340932A (zh) 2009-01-07
RU2006147284A (ru) 2008-08-27
BRPI0513715A (pt) 2008-05-13
MX2007000421A (es) 2007-03-28
CA2574124A1 (fr) 2006-02-02
IL180229A0 (en) 2007-07-04
DE102004035606A1 (de) 2006-03-30

Similar Documents

Publication Publication Date Title
CA2383470C (fr) Inhibition de la secretion de cellules non neuronales
RU2412253C2 (ru) Рекомбинантная экспрессия белков в двухцепочечной форме с дисульфидным мостиком
US6051239A (en) Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US8852603B2 (en) Inhibition of secretion from non-neuronal cells
AU2001285688B2 (en) Protein complex serving as a vehicle for orally administerable medicaments
TWI642444B (zh) 糖鏈加成連接基、含有糖鏈加成連接基與生理活性物質的化合物或其鹽，以及其製造方法
EP1523336B1 (fr) Agents cibles de regeneration des nerfs
AU2005266739A1 (en) Carrier for medicaments for obtaining oral bioavailability
KR102227918B1 (ko) 당쇄 부가 링커, 당쇄 부가 링커 부분과 생리 활성 물질 부분을 함유하는 화합물 또는 그의 염, 및 이들의 제조 방법
CN102949731A (zh) 与glp-2受体特异性结合的药物融合体
WO2019190970A1 (fr) Compositions, procédés et systèmes pour protéine fondée sur l'affinité pouvant être administrée par voie orale
AU2008241572B2 (en) Inhibition of secretion from non-neuronal cells
Reidy Engineering of the RTB lectin as a carrier platform for proteins and antigens
CN103509119A (zh) 一种短肽激素与重组假单胞菌外毒素a的重组融合蛋白及应用
WO2007118889A1 (fr) Protéase spécifique pour l'inactivation du facteur de nécrose tumorale alpha humain

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 14 JUN 2009.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application